Income Tax Expense (Benefit) in USD of ELITE PHARMACEUTICALS INC /NV/ from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly/annual Income Tax Expense (Benefit) history and change rate from Q2 2010 to Q3 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Income Tax Expense (Benefit) for the quarter ending 30 Sep 2025 was $1.99M.
  • ELITE PHARMACEUTICALS INC /NV/ annual Income Tax Expense (Benefit) for 2024 was $4.26M.
  • ELITE PHARMACEUTICALS INC /NV/ annual Income Tax Expense (Benefit) for 2023 was -$19.6M.
  • ELITE PHARMACEUTICALS INC /NV/ annual Income Tax Expense (Benefit) for 2022 was $424K.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $1.99M* +$471K 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 $5.32M* +$5.09M 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q4 2024 $239K +$1.04M 01 Oct 2024 31 Dec 2024 10-Q 13 Feb 2025
Q3 2024 $1.52M* +$19.2M 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 $232K +$77K +49.7% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q4 2023 -$17.9M -$801K -$840K -2140% 01 Oct 2023 31 Dec 2023 10-Q 13 Feb 2025
Q3 2023 -$17.1M -$17.7M* -$17.7M 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 $579K $155K +$155K 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024
Q1 2023 $424K $373K 01 Jan 2023 31 Mar 2023 10-K 01 Jul 2024
Q4 2022 $39.3K 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024
Q3 2022 $11.6K +$7.59K +190% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 $0 01 Apr 2022 30 Jun 2022 10-Q 15 Aug 2022
Q3 2021 $4K +$1.5K +60% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q3 2020 $2.5K 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021
Q2 2020 -$946K 01 Apr 2020 30 Jun 2020 10-Q 14 Aug 2020
Q2 2018 -$1.05M $0 -$3K -100% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2018
Q1 2018 -$1.05M $3K +$3K 01 Jan 2018 31 Mar 2018 10-K 14 Jun 2018
Q4 2017 -$1.05M -$1.05M -$2.92M 01 Oct 2017 31 Dec 2017 10-Q 11 Feb 2019
Q3 2017 $1.87M $0 $0 01 Jul 2017 30 Sep 2017 10-K 14 Jun 2018
Q2 2017 $1.87M $3K +$6K 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018
Q1 2017 $1.87M $0 +$520K 01 Jan 2017 31 Mar 2017 10-K 14 Jun 2018
Q4 2016 $1.35M $1.87M* +$1.87M 01 Oct 2016 31 Dec 2016 10-K 14 Jun 2018
Q3 2016 -$523K $0 $0 01 Jul 2016 30 Sep 2016 10-K 14 Jun 2018
Q2 2016 -$523K -$3K -$3K 01 Apr 2016 30 Jun 2016 10-K 14 Jun 2018
Q1 2016 -$520K -$520K -$517K -17233% 01 Jan 2016 31 Mar 2016 10-K 14 Jun 2018
Q4 2015 -$3K $0 $0 01 Oct 2015 31 Dec 2015 10-K 14 Jun 2018
Q3 2015 -$3K $0 $0 01 Jul 2015 30 Sep 2015 10-K 14 Jun 2018
Q2 2015 -$3K $0 $0 01 Apr 2015 30 Jun 2015 10-K 14 Jun 2018
Q1 2015 -$3K -$3K +$292K +99% 01 Jan 2015 31 Mar 2015 10-K 14 Jun 2017
Q4 2014 -$295K $0 $0 01 Oct 2014 31 Dec 2014 10-K 14 Jun 2017
Q3 2014 -$295K $0 -$2K -100% 01 Jul 2014 30 Sep 2014 10-K 14 Jun 2017
Q2 2014 -$293K $0 $0 01 Apr 2014 30 Jun 2014 10-K 14 Jun 2017
Q1 2014 -$293K -$295K 01 Jan 2014 31 Mar 2014 10-K 15 Jun 2016
Q4 2013 $0 $0 01 Oct 2013 31 Dec 2013 10-K 15 Jun 2016
Q3 2013 $2K +$977 +95.5% 01 Jul 2013 30 Sep 2013 10-K 15 Jun 2016
Q2 2013 $0 -$3K -100% 01 Apr 2013 30 Jun 2013 10-K 15 Jun 2016
Q4 2012 $0 $0 01 Oct 2012 31 Dec 2012 10-Q 14 Feb 2013
Q3 2012 $1.02K +$1.02K 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2012
Q2 2012 $3K +$500 +20% 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2012
Q4 2011 $0 -$1.06K -100% 01 Oct 2011 31 Dec 2011 10-Q 14 Feb 2013
Q3 2011 $0 -$1.04K -100% 01 Jul 2011 30 Sep 2011 10-Q 14 Nov 2012
Q2 2011 $2.5K +$2.5K 01 Apr 2011 30 Jun 2011 10-Q 14 Aug 2012
Q4 2010 $1.06K 01 Oct 2010 31 Dec 2010 10-Q 14 Feb 2012
Q3 2010 $1.04K 01 Jul 2010 30 Sep 2010 10-Q 14 Nov 2011
Q2 2010 $0 01 Apr 2010 30 Jun 2010 10-Q/A 19 Aug 2011

ELITE PHARMACEUTICALS INC /NV/ Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $4.26M* +$23.9M 01 Apr 2024 31 Mar 2025 10-K 30 Jun 2025
2023 -$19.6M* -$20.1M 01 Apr 2023 31 Mar 2024 10-K 30 Jun 2025
2022 $424K +$2.16M 01 Apr 2022 31 Mar 2023 10-K 01 Jul 2024
2021 -$1.74M* 01 Apr 2021 31 Mar 2022 10-K 29 Jun 2023
2018 -$676K +$370K +35.4% 01 Apr 2018 31 Mar 2019 10-K 29 Jun 2020
2017 -$1.05M +$822K 01 Apr 2017 31 Mar 2018 10-K 21 Jun 2019
2016 -$1.87M* -$1.35M 01 Apr 2016 31 Mar 2017 10-K 14 Jun 2018
2015 -$520K -$517K -15919% 01 Apr 2015 31 Mar 2016 10-K 14 Jun 2018
2014 -$3.25K +$289K +98.9% 01 Apr 2014 31 Mar 2015 10-K 14 Jun 2017
2013 -$293K 01 Apr 2013 31 Mar 2014 10-K 15 Jun 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.